Percutaneous edge to edge systemic tricuspid valve repair for the treatment of severe tricuspid valve regurgitation in patients with systemic right ventricle: The first descriptive cohort

Abstract

Patients with systemic right ventricle (mostly congenitally-corrected transposition of the great arteries or transposition of the great arteries corrected by atrial switch) commonly develop significant systemic tricuspid valve regurgitation and systemic right ventricular dysfunction in adulthood, both of which presenting a therapeutic dilemma for the care team. Percutaneous edge-to-edge repair could be a alternative to surgery. Seven high-risk surgical patients with severe systemic tricuspid regurgitation undergoing a percutaneous repair were included between July 2020 and March 2021. Our study is a prospective analysis of short and mid-term clinical, biological, echocardiographic and MRI outcomes with an expected minimum follow-up of 2 years. The first data tend to show a significant benefit of the repair on clinical status (dyspnea severity, quality of life, test exercise performance), a decrease of BNP level and an improvement of tricuspid regurgitation and right ventricular volume and function measured by echocardiography and MRI. Besides, the rate of failure and complications seems to be very low. Percutaneous edge-to-edge repair of systemic tricuspid regurgitation might be a safe and effective therapeutic option in high-risk surgical adult patients.